POINT Biopharma Global Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

POINT Biopharma Global şirketinin toplam hissedar öz sermayesi $424.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $477.7M ve $53.5M dir. POINT Biopharma Global 'in FAVÖK'ü $107.8M faiz karşılama oranı -7.1 dur. Şirketin $339.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-7.1x
Nakit	US$339.16m
Eşitlik	US$424.19m
Toplam yükümlülükler	US$53.51m
Toplam varlıklar	US$477.70m

Son finansal sağlık güncellemeleri

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

Recent updates

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

Aug 20

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PNT 'nin kısa vadeli varlıkları ( $353.2M ) kısa vadeli yükümlülüklerini ( $38.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: PNT şirketinin kısa vadeli varlıkları ( $353.2M ) uzun vadeli yükümlülüklerini ( $14.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PNT borçsuzdur.

Borcun Azaltılması: PNT un 5 yıl önce borcu yoktu.

Borç Kapsamı: PNT un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: PNT şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

POINT Biopharma Global Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Recent updates

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

Price target decreased by 19% to US$13.85

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 24%

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

New major risk - Share price stability

Price target decreased by 9.2% to US$15.44

Investor sentiment improves as stock rises 81%

Consensus revenue estimates fall by 54%

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

High number of new directors

POINT Biopharma Global Inc. Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress

Point Biopharma Global Inc. Appoints Bridget Martell to Its Board of Directors

Consensus EPS estimates upgraded to US$0.80 loss

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

Price target increased by 7.3% to US$16.90

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 18%

Independent Director exercised options to buy US$122k worth of stock.

Forecast to breakeven in 2024

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial

POINT Biopharma Global Inc. Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Executive Chairman recently bought US$311k worth of stock

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to US$19.00

High number of new directors

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, A Next-Generation PSMA Ligand, At EANM's Annual Congress

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Point Biopharma plummets on announcing common stock offering

Price target increased to US$21.00

POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05

POINT Biopharma Announces Appointment of Chris Horvath as Executive Vice President, Commercial

Chief Medical Officer & Director recently sold US$4.2m worth of stock

POINT Biopharma Global Inc. Unveils FRONTIER: A Pan-Cancer Fap-A Targeted Clinical Program

POINT Biopharma Global Inc. Confirms No Supply Shortages of 177Lu-PNT2002 for the Splash Trial

High number of new and inexperienced directors

POINT Biopharma Global Announces First Patient in European Union (EU) Dosed in the Phase 3 Splash Trial

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH Trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

POINT Biopharma Global Inc., Annual General Meeting, Jun 02, 2022

High number of new and inexperienced directors

POINT Biopharma Global Inc. Releases New Data and Exercises Option for Best-In-Class FAP Inhibitor

POINT Biopharma Global Inc. Announces Initiation of Randomization for Its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of Its Phase 3 SPLASH Study of PNT2002 for mCRPC

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin